KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Hims & Hers Health (HIMS) Other Operating Expenses (2020 - 2025)

Hims & Hers Health (HIMS) has disclosed Other Operating Expenses for 6 consecutive years, with $318.1 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 13.95% to $318.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 39.45% year-over-year, with the annual reading at $1.2 billion for FY2025, 39.45% up from the prior year.
  • Other Operating Expenses hit $318.1 million in Q4 2025 for Hims & Hers Health, up from $309.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $318.1 million in Q4 2025 to a low of $27.0 million in Q1 2021.
  • Historically, Other Operating Expenses has averaged $157.5 million across 5 years, with a median of $142.1 million in 2023.
  • Biggest YoY gain for Other Operating Expenses was 238.37% in 2021; the steepest drop was 3.97% in 2021.
  • Year by year, Other Operating Expenses stood at $56.6 million in 2021, then soared by 91.09% to $108.1 million in 2022, then surged by 46.89% to $158.7 million in 2023, then surged by 75.87% to $279.2 million in 2024, then increased by 13.95% to $318.1 million in 2025.
  • Business Quant data shows Other Operating Expenses for HIMS at $318.1 million in Q4 2025, $309.0 million in Q3 2025, and $284.4 million in Q2 2025.